Over the past decade, European biotech has seen remarkable growth, driven by increasing early-stage investments and the creation of promising start-ups. VIB, a leading life sciences research institute in Belgium, has played a central role in this transformation, having launched 39 spin-offs with over €1.8 billion in venture capital. Venture capital firms like V-Bio Ventures have been critical in supporting these early stage biotech companies, leading to a wave of exciting companies advancing toward late-stage clinical trials. As Europe’s biotech ecosystem is entering a crucial scale-up phase, significant funding gaps remain. European scale-up capital is five times lower than in the US, presenting attractive opportunities for global investors looking to tap into high-growth companies with strong innovation pipelines. Panelists will discuss the value generation possible within the thriving European bioetch sector, and examine the increasing deal flow that Europe offers through it’s high-impact, high-return opportunities.